Results 151 to 160 of about 205,200 (274)

Albuminuria Predicts a Rapid Decline in Kidney Function in 2 International, Longitudinal Cohorts of Adults With Sickle Cell Anemia

American Journal of Hematology, Volume 101, Issue 2, Page 304-310, February 2026.
ABSTRACT Chronic kidney disease (CKD) is common and a major contributor to increased morbidity and early mortality in people with sickle cell anemia (SCA). Urine albumin‐to‐creatinine ratio (uACR) is recommended to identify patients with SCA‐related CKD but its utility in predicting long‐term kidney dysfunction remains unclear in this patient ...
Pablo Bartolucci, Étienne Audureau, Vincent Audard, Frédéric Galactéros, Guillaume Lettre, Charmaine Anthony, Olufolake Egbujo, Jin Han, Maria Armila Ruiz, James P. Lash, Victor R. Gordeuk, Xu Zhang, Santosh L. Saraf   +12 more
wiley   +1 more source

Reaching Community Through School Going Children for Sickle Cell Disease in Zankhvav Village of Surat District, Western India [PDF]

, 2012
Objectives: The objective of the study was to explore a method to reach the community via school going adolescents for screening tribal people for Sickle Cell disease.
Bansal, R, Gharat, VV, Mallick, KH, Rupani, MP, Vasava, BC   +4 more
core   +1 more source

Versatile Cell Penetrating Peptide for Multimodal CRISPR Gene Editing in Primary Stem Cells

Advanced Functional Materials, Volume 36, Issue 5, 15 January 2026.
CRISPR machinery in diverse molecular formats (DNA, RNA, and ribonucleic protein) is complexed into nanoparticles with the cell‐friendly arginine‐alanine‐leucine‐alanine (RALA) cell‐penetrating peptide. Nanoparticles are delivered to primary mesenchymal stem cells ex vivo or locally in vivo to facilitate multimodal CRISPR gene editing. This RALA‐CRISPR
Joshua P. Graham, Jose Gabriel Castro, Lisette C. Werba, Joseph Amitrano, Luke Fardone, Kevin P. Francis, Anand Ramamurthi, Michael J. Layden, Helen O. McCarthy, Tomas Gonzalez‐Fernandez   +9 more
wiley   +1 more source

Sickle Cell Anemia : a Psychosocial Study of Attitudes and Effect [PDF]

, 1973
This research study was focused on two broad areas of exploration. The first area deals with the identification of various factors affecting a family when a family member has the anemia or symptomatic form of sickle cell disease.
Gilmore, Marian Genita, Goddard, Sharon Ann   +1 more
core   +1 more source

Protein S Enhances the Phagocytosis of Phosphatidylserine‐Exposing Erythrocytes: Implications in Sickle Cell Disease

American Journal of Hematology, Volume 101, Issue 1, Page 26-40, January 2026.
ABSTRACT The major anticoagulant Protein S (PROS1) also contributes to the phagocytosis of apoptotic cells by bridging exposed phosphatidylserine (PtdSer) to the MerTK receptor on macrophages (efferocytosis). Whether PROS1 is involved in the splenic clearance of PtdSer‐positive senescent and altered erythrocytes such as erythrocyte ghosts (eryghosts ...
Claire Auditeau, Aurélie Fricot, Raphaël Gauthier, Abdoulaye Sissoko, Zeynep Cacan, Céline Gounou, Laure Joseph, Sandra Manceau, Slimane Allali, Michael Dussiot, Mickael Marin, Alexis Lavergne, Mariem Khamari, Sophie Moog, Elsa Bianchini, Laetitia Claer, Sandrine Laurance, Valentine Brousse, Sébastien Eymieux, Philippe Roingeard, Pascal Amireault, Thiago Trovati Maciel, Alain Brisson, Pierre Buffet, François Saller, Delphine Borgel, Camille Roussel   +26 more
wiley   +1 more source

Unveiling the Genetic Association Between Hemoglobin Concentration and Amyotrophic Lateral Sclerosis

Brain and Behavior, Volume 16, Issue 1, January 2026.
This study identified a causal relationship between genetically predicted hemoglobin (Hb) concentration and amyotrophic lateral sclerosis (ALS) through Mendelian randomization (MR), and integrated RNA‐seq and RT‐qPCR analyses to highlight BACH1, FLVCR1, and TRIM58 as potential genes involved in this association.
Hongmei Luo, Yujie Yang, Xiaojian Cao, Chunchu Deng, Hong Chen   +4 more
wiley   +1 more source

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 120-130, January 2026.
The investigational agent osivelotor, a small molecule hemoglobin (Hb) modifier in development for the treatment of sickle cell disease (SCD), acts by increasing Hb‐oxygen affinity and inhibiting the polymerization of sickle Hb. We report safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first two phase 1 clinical trials of ...
Eleanor A. Lisbon, R. Clark Brown, Andrew Redfern, Ken Duchin, Aline Barth, Erika S. Roberts, Polo Gaputan, Kobina Dufu, Arthur Lo, Mira Patel Pochron, David R. Archer, Wai Chin, Karena Kong, Carla B. Washington, Adeyemi Adenola, Eric I. Zimmerman   +15 more
wiley   +1 more source

MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients

HemaSphere, Volume 10, Issue 1, January 2026.
ABSTRACT Administration of memantine, an antagonist of the N‐methyl‐ d‐aspartate receptor, prevents Ca2+ overload and dehydration of red blood cells (RBCs) in patients with sickle cell disease (SCD). The objectives of the 1‐year dose‐escalation Phase IIa/IIb Memantine trial (MeMAGEN – NCT 03247218) with 17 SCD patients who were under stable ...
Ariel Koren, Carina Levin, Leonid Livshits, Fabio Valeri, Sari Peretz, Sivan Raz, Anna Yu Bogdanova, Max Gassmann   +7 more
wiley   +1 more source

Apneia obstrutiva do sono em portadores da anemia falciforme Obstructive sleep apnea in sickle cell disease carriers

Revista Brasileira de Hematologia e Hemoterapia, 2010
A Síndrome da Apneia Obstrutiva do Sono (SAOS) é definida como episódios recorrentes de obstrução completa ou parcial das vias aéreas superiores que ocorrem durante o sono.
Cristina Salles, Regina T. T. Ramos, Marcos A. Matos   +2 more
doaj  

Campus Update: January/February 1993 v. 5, no. 1 [PDF]

, 1993
Monthly newsletter of the BU Medical ...
Boston University Medical Center
core   +1 more source